BIOMARKER:

FGFR mutation

A2 | Sensitive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

A2 | Resistant

C2 | Resistant

C3 | Resistant

D | Resistant

Urothelial Cancer

Cholangiocarcinoma

Solid Tumor

Pancreatic Cancer

Gallbladder Cancer

Salivary Gland Cancer

Head and Neck Cancer

Glioblastoma

Astrocytoma

Non Small Cell Lung Cancer

Squamous Cell Carcinoma of Head and Neck

Uterine Cancer

Breast Cancer

erdafitinib

FGFR mutation|Urothelial Cancer|erdafitinib

FGFR mutation|Cholangiocarcinoma|erdafitinib

FGFR mutation|Pancreatic Cancer|erdafitinib

FGFR mutation|Salivary Gland Cancer|erdafitinib

FGFR mutation|Glioblastoma|erdafitinib

pemigatinib

FGFR mutation|Urothelial Cancer|pemigatinib

FGFR mutation|Cholangiocarcinoma|pemigatinib

FGFR mutation|Pancreatic Cancer|pemigatinib

FGFR mutation|Gallbladder Cancer|pemigatinib

FGFR mutation|Head and Neck Cancer|pemigatinib

FGFR mutation|Astrocytoma|pemigatinib

FGFR mutation|Non Small Cell Lung Cancer|pemigatinib

FGFR mutation|Uterine Cancer|pemigatinib

ponatinib

FGFR mutation|Cholangiocarcinoma|ponatinib

ICP-192

FGFR mutation|Solid Tumor|ICP-192

erdafitinib + JNJ-63723283

FGFR mutation|Urothelial Cancer|erdafitinib + JNJ-63723283

CPL304110

FGFR mutation|Solid Tumor|CPL304110

nintedanib

FGFR mutation|Squamous Cell Carcinoma of Head and Neck|nintedanib

FGFR inhibitor

FGFR mutation|Urothelial Cancer|FGFR inhibitor

ABSK121

FGFR mutation|Solid Tumor|ABSK121

E7090

FGFR mutation|Breast Cancer|E7090